Did you even watch the segment? She asked him if
Post# of 148190
And when she asked, he said there might be a different therapeutic way down the road, and talked about starting out in animal models and then on to Phase 1 trials, etc. It wasn't that he didn't name LL (which I would have loved but didn't at all expect) that really got to me, but that he didn't talk about immune system treatments as a class at all, when it seems they are the most promising treatments for the s/c class of cases.